Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 5/20 | 0.47 |
| ▸ | BACE1 | P56817 | 5/20 | 0.41 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | REN | P00797 | 4/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | TERF2 | Q15554 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15727190 | 0.96 | CTSD (0.47) | CTSDBACE1ADAM17RENCA1 | |
| SCHEMBL15727219 | 0.96 | CTSD (0.48) | CTSDBACE1CA1CA2TERF2 | |
| SCHEMBL15727173 | 0.95 | CTSD (0.46) | CTSDBACE1ADAM17RENCA1 | |
| SCHEMBL15750326 | 0.95 | CTSD (0.46) | CTSDBACE1ADAM17RENCA1 | |
| SCHEMBL23736231 | 0.93 | CTSD (0.40) | CTSDBACE1ADAM17RENCA1 | |
| SCHEMBL15727249 | 0.92 | CTSD (0.47) | CTSDBACE1CA1CA2TERF2 | |
| SCHEMBL15727185 | 0.91 | CTSD (0.46) | CTSDBACE1ADAM17CA1CA2 | |
| SCHEMBL23736076 | 0.90 | CTSD (0.39) | CTSDBACE1ADAM17RENCA1 | |
| SCHEMBL23736081 | 0.89 | CTSD (0.41) | CTSDBACE1ADAM17RENCA1 | |
| SCHEMBL15727308 | 0.87 | ADAM17 (0.40) | BACE1ADAM17RENCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9309285-B2 | Macrocyclic broad spectrum antibiotics | RQX PHARMACEUTICALS, INC. (US) | 2016-04-12 | — | — | US | disclosed |
| WO-2014081886-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS, INC. (US) | 2014-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140142029-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CTSD 271/4885BACE1 44/4885ADAM17 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.